72 related articles for article (PubMed ID: 6304889)
21. Sustained benefits or oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure.
Shellock FG; Shah PK; Berman DS; Rubin SA; Singh BN; Swan HJ
Clin Pharmacol Ther; 1980 Oct; 28(4):436-40. PubMed ID: 7408403
[TBL] [Abstract][Full Text] [Related]
22. Determination of ejection fraction by echocardiography in patients treated with P.E.T.N.
Arce-Gomez E; Aspe y Rosas J; Alcocer Diaz Barreiro L
Nouv Presse Med; 1980 Sep; 9(34 Suppl):2458-61. PubMed ID: 7422535
[TBL] [Abstract][Full Text] [Related]
23. Antianginal effects of pentaerythritol tetranitrate.
Arce-Gomez E; Aspe y Rosas J; Alcocer Diaz Barreiro L; Diaz Barreiro AL
Nouv Presse Med; 1980 Sep; 9(34 Suppl):2487-91. PubMed ID: 6775303
[TBL] [Abstract][Full Text] [Related]
24. Short-term hemodynamic effects of cardiac resynchronization therapy in patients with heart failure, a narrow QRS duration, and no dyssynchrony.
Williams LK; Ellery S; Patel K; Leyva F; Bleasdale RA; Phan TT; Stegemann B; Paul V; Steendijk P; Frenneaux M
Circulation; 2009 Oct; 120(17):1687-94. PubMed ID: 19822812
[TBL] [Abstract][Full Text] [Related]
25. [Hemodynamic effects of one administration of l-dopa in patients with left ventricular heart failure (introductory remarks)].
Leszek P; Zieliński T; Korewicki J
Kardiol Pol; 1993 May; 38(5):335-9. PubMed ID: 8366641
[TBL] [Abstract][Full Text] [Related]
26. Pentaerythrityl tetranitrate improves the outcome of children born to mothers with compromised uterine perfusion-12-months follow-up and safety data of the double-blind randomized PETN trial.
Groten T; Lehmann T; Städtler M; Komar M; Winkler JL; Condic M; Strizek B; Seeger S; Jäger Y; Pecks U; Eckmann-Scholz C; Kagan KO; Hoopmann M; von Kaisenberg CS; Hertel B; Tauscher A; Schrey-Petersen S; Friebe-Hoffmann U; Lato K; Hübener C; Delius M; Verlohren S; Sroka D; Schlembach D; de Vries L; Kraft K; Seliger G; Schleußner E;
Am J Obstet Gynecol MFM; 2024 Apr; 6(4):101332. PubMed ID: 38460823
[TBL] [Abstract][Full Text] [Related]
27. Effects of expiring reimbursability of pentaerythrityl tetranitrate (PETN, pentalong®) on anti-anginal therapy: an observational study.
Grimmsmann T; Chenot JF; Angelow A
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):803-11. PubMed ID: 26043680
[TBL] [Abstract][Full Text] [Related]
28. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
Givertz MM; Hare JM; Loh E; Gauthier DF; Colucci WS
J Am Coll Cardiol; 1996 Dec; 28(7):1775-80. PubMed ID: 8962566
[TBL] [Abstract][Full Text] [Related]
29. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study.
Pornin M; Harpey C; Allal J; Sellier P; Ourbak P
Clin Trials Metaanal; 1994 Apr; 29(1):49-56. PubMed ID: 10150185
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacokinetics of nitrate derivatives: recent data].
Baligadoo S; Chiche P
Coeur Med Interne; 1979; 18(2):263-8. PubMed ID: 114351
[No Abstract] [Full Text] [Related]
31. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
Wagner F; Yeter R; Bisson S; Siniawski H; Hetzer R
Crit Care Med; 2003 May; 31(5):1421-8. PubMed ID: 12771613
[TBL] [Abstract][Full Text] [Related]
32. Symptomatic and hemodynamic benefit of pentaerythrityl tetranitrate and hydralazine in a case of congestive heart failure.
Gori T; Münzel T
Clin Res Cardiol; 2009 Oct; 98(10):677-9. PubMed ID: 19644645
[No Abstract] [Full Text] [Related]
33. Cardiac function and hemodynamic parameters after pentaerythritol tetranitrate. Assessment by new noninvasive radionuclide technique.
Winsor T
Nouv Presse Med; 1980 Sep; 9(34 Suppl):2465-9. PubMed ID: 7422536
[TBL] [Abstract][Full Text] [Related]
34. Bronchopulmonary effects of pentaerythrityl tetranitrate and isoproterenol.
Aviado DM; Kishimoto T; Kneidinger HJ
J Pharmacol Exp Ther; 1969 Feb; 165(2):274-85. PubMed ID: 5763062
[No Abstract] [Full Text] [Related]
35. [Methods for the study of anti-anginal agents].
Winsor T
Munch Med Wochenschr; 1972 Mar; 114(10):463-5. PubMed ID: 4625983
[No Abstract] [Full Text] [Related]
36. Cardiac function and hemodynamic parameters after pentaerythritol tetranitrate: assessment by a noninvasive radionuclide technique.
Winsor D; Winsor T
Angiology; 1979 Apr; 30(4):266-75. PubMed ID: 443593
[TBL] [Abstract][Full Text] [Related]
37. Effects of piridoxilate, a glyoxylic acid derivative, on the energy metabolism of the heart.
Otorii T; Katano Y; Takeda K; Imai S
Jpn Heart J; 1980 Nov; 21(6):845-57. PubMed ID: 7463722
[TBL] [Abstract][Full Text] [Related]
38. [Letter: Loss of efficacy in long-term nitrites?].
Bleifeld W
Dtsch Med Wochenschr; 1973 Oct; 98(40):1885. PubMed ID: 4762052
[No Abstract] [Full Text] [Related]
39. Pentaerythrityl tetranitrate (PETN): a better nitrate?
Rutherford E; Struthers AD
Eur Heart J; 2019 Dec; 40(46):e23-e25. PubMed ID: 24126881
[No Abstract] [Full Text] [Related]
40. Organic Nitrates in Heart Failure Revisited: Pentaerythritol Tetranitrate Induces Heme Oxygenase 1 to Protect the Myocardium.
Wenzel P
Hypertension; 2015 Nov; 66(5):933-4. PubMed ID: 26351029
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
